Radiotherapy after prostatectomy

Tumori

Volumn 88, Issue 6, 2002, Pages 445-452

  Sanguineti, Giuseppe ^a,b   Franzone, Paola ^b   Culp, Laura ^a   Marcenaro, Michela ^b   Barra, Salvina ^b   Vitale, Vito ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant radiotherapy; Prostate carcinoma; Prostatectomy; Salvage radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; HUMAN; PRACTICE GUIDELINE; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0036880297     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800602     Document Type: Review

References (73)

1. Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am, 24: 395-406, 1997.
2. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, 152: 1850-1857, 1994.
3. Trapasso JG, deKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821-1825, 1994.
4. Catalona WJ. Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol, 152: 1837-1842, 1994.
5. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol, 152: 1714-1520, 1994.
6. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499-1507, 1999.
7. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD: Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol, 19: 3692-3705, 2001.
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591-1597, 1999.
9. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol, 165: 1146-1151, 2001.
10. Diamandis EP, Yu H: New biological functions of prostatespecific antigen? J Clin Endocrinol Metab, 80: 1515-1517, 1995.
11. Schellhammer PF, el-Mahdi AM, Kuban DA, Wright GL Jr: Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. Urol Clin North Am, 24: 407-414, 1997.
12. Morgan BR, Tarter TH: Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol, 166: 2311-2312, 2001.
13. Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ: Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer. 83: 1432-1436, 2000.
14. Parker C, Warde P, Catton C: Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol, 61: 107-116, 2001.
15. Anscher MS: Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer, 20; 96: 91-93, 2001.
16. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA, Martinez AA: Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology, 54: 111-117, 1999.
17. Peschel RE, Robnett TJ, Hesse D, King CR, Ennis RD, Schiff PB, Wilson LD: PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients. Int J Cancer, 90: 29-36, 2000.
18. Weigel T, Hinkelbein W: Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation. Front Radiat Ther Oncol, 36: 35-42, 2002.
19. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigni RG: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol, 156: 1725-1729, 1996.
20. Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T, Porter AT: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol, 158: 1436-1439, 1997.
21. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys, 38: 731-736, 1997.
22. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol, 159: 173-177, 1998.
23. Anscher MS, Clough R, Dodge R: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys, 48: 369-375, 2000.
24. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol, 163: 845-850, 2000.
25. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 19: 1030-1039, 2001.
26. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A: Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys, 52: 674-680, 2002.
27. Katz MS, Zelefsky MJ, Venkatraman NS, Fuks Z, Lee HJ, Hummer A, Leibel SA: Risk stratification predicts biochemical outcome ater salvage post-prostatectomy three-dimensional conformal radiation therapy. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 170, 2001.
28. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM, Carroll PR: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol, 159: 1437-1443, 1998.
29. Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE, Sherman NE: The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer, 68: 2370-2377, 1991.
30. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys, 21: 537-547, 1991.
31. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol, 17: 1155, 1999.
32. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM, Barrett DM, Rife CC, Gonchoroff NJ: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer, 70: 311-323, 1992.
33. Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI: Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol, 152: 1077-1081, 1994.
34. Golimbu M, Provet J, Al-Askari S, Morales P: Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology, 30: 427-435, 1987.
35. Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH: Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol, 166: 2198-2201, 2001.
36. Anscher MS, Prosnitz LR: Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys, 21: 941-947, 1991.
37. Formenti SC, Lieskovsky G, Simoneau AR, Skinner D, Groshen S, Chen SC, Petrovich Z: Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. J Urol, 155: 616-619, 1996.
38. Kaplan ID, Bagshaw MA: Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology, 39: 401-406, 1992.
39. Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology, 41: 113-120, 1993.
40. Lightner DJ, Lange PH, Reddy PK, Moore L: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol, 144: 921-926, 1990.
41. Wiegel T, Hinkelbein W, Steiner U, Miller K: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol, 157: 965-966, 1997.
42. Link P, Freiha FS, Stamey TA: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol, 145: 532-534, 1991.
43. Coetzee LJ, Hars V, Paulson DF: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology, 47: 232-235, 1996.
44. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341: 1781-1788, 1999.
45. Zietman AL, Prince EA, Nakfoor BM, Shipley WU: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology, 49: 74-83, 1997.
46. Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich ML: Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys, 51: 1002-1007, 2001.
47. Do T, Dave G, Parker R, Kagan AR: Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. Int J Radiat Oncol Biol Phys, 50: 1220-1225, 2001.
48. Anscher MS: Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution? Int J Radiat Oncol Biol Phys, 34: 745-747, 1996.
49. Zietman AL, Coen JJ, Shipley WU, Althausen AF: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology, 42: 292-298, 1993.
50. Petrovich Z, Lieskovsky G, Langholz B, Bochner B, Formenti S, Streeter O, Skinner DG: Adjuvant radiotherapy in patients with pathologic Stage C (pT3N0) adenocarcinoma of the prostate. Urology, 53: 1184-1193, 1999.
51. Yamada AH, Lieskovsky G, Petrovich Z, Chen SC, Groshen S, Skinner DG: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC. prostate cancer. Am J Clin Oncol, 17: 277-285, 1994.
52. Petrovich Z, Lieskovsky G, Langholz B, Formenti S, Baert L, Streeter O, Skinner DG: Radical prostatectomy and postopertive irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 40: 139-147, 1998.
53. Corn BW, Winter K, Pilepich MV: Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Urology, 54: 495-502, 1999.
54. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H: Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol, 163: 1178-1182, 2000.
55. Valicenti RK, Gomella LG, Ismail M, Mullholland SG, Petersen RO, Corn BW: Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer, 82: 1909-1914, 1998.
56. Taylor NA, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A: Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 317, 2001.
57. Cozzarini C, Ceresoli GL, Bolognesi A, Bertini R, Da Pozzo L, Fiorino C, Cattaneo M, Villa E: Importance of time to radiotherapy and lack of evidence for the use of adjuvant androgen ablation in 165 node-negative prostate cancer treated with radical prostatectomy and adjuvant radiotherapy. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 281-282, 2001.
58. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499-1507, 1999.
59. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, Scardino PT, Kattan MW: Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol, 20: 951-956, 2002.
60. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol, 152: 1826-1830, 1994.
61. Epstein JI: Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am, 23: 651-663, 1996.
62. Kupelian PA, Katcher J, Levin HS, Klein EA: Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys, 37: 1043-1052, 1997.
63. Pollack A, Smith LG: Adjuvant external beam radiation therapy postprostatectomy. In: Prostate cancer: principles and practice, Kantoff PW, Carroll PR, D'Amico AV (Eds), Lippincott Williams and Wilkins, Philadelphia, 2002.
64. Wiegel T, Bressel M, Carl UM: Adjuvant radiotherapy following radical prostatectomy-results of 56 patients. Eur J Cancer, 31A: 5-11, 1995.
65. Grossfeld GD, Tigrani VS, Nudell D, Roach M 3rd, Weinberg VK, Presti JC Jr, Small EJ, Carroll PR: Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol, 164: 93-99, 2000.
66. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am, 28: 555-565, 2001.
67. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC: Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol, 165: 864-866, 2001.
68. Lightner DJ, Lange PH, Reddy PK, Moore L: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol, 144: 921-926, 1990.
69. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, Ferrigni RG: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc, 69: 613-619, 1994.
70. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW: Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys, 42: 501-506, 1998.
71. Zagars GK, Pollack A, von Eschenbach AC: Addition of radition therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology, 58: 233-239, 2001.
72. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys, 41: 735-740, 1998.
73. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H: Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol, 167: 117-122, 1998.